BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 14/06/2002

FDA Releases Draft Guidance on Assessing QT Interval Prolongation Risk in Pharmaceutical Studies

The FDA has made available a draft guidance document outlining principles for identifying the risk of QT interval prolongation in pharmaceuticals, aimed at protecting patients from life-threatening arrhythmias

Source: Federal Register — Food and Drug AdministrationOpen original release →